PubRank

Silvia Buonamici

Author PubWeight™ 33.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011 5.78
2 The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007 4.04
3 Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008 3.57
4 Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2006 2.35
5 Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med 2008 2.19
6 A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med 2011 1.97
7 Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell 2009 1.84
8 Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med 2010 1.77
9 Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med 2013 1.19
10 Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 2004 1.04
11 Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts. Haematologica 2003 0.92
12 AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation. Cancer Res 2004 0.83
13 Notches, NFkappaBs and the making of T cell leukemia. Cell Cycle 2007 0.80
14 Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem 2013 0.79
15 Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line. Org Lett 2014 0.78
16 P/CAF and GCN5 acetylate the AML1/MDS1/EVI1 fusion oncoprotein. Biochem Biophys Res Commun 2003 0.77
17 Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol 2004 0.76
18 Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med 2016 0.76
19 Hexamethylene bisacetamide as a treatment for T-cell leukemia (T-ALL). Leuk Res 2007 0.75
20 Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. Haematologica 2004 0.75
21 Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in complete hematologic remission. Haematologica 2004 0.75
22 Two more inv(16) acute myeloid leukemia cases with infrequent CBFbeta-MYH11 fusion transcript: clinical and molecular findings. Haematologica 2002 0.75